TD Cowen lowered the firm’s price target on GeneDx (WGS) to $55 from $60 and keeps a Buy rating on the shares. The firm updated its model following a braod-based miss on Q1 results. Bright spots were Exome volumes and guidance reset which have put the stock in a de-risked position.
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on WGS:
- GeneDx price target lowered to $90 from $170 at BTIG, removed from Top Picks
- GeneDx price target lowered to $70 from $100 at Guggenheim
- GeneDx price target lowered to $75 from $100 at Canaccord
- GeneDx price target lowered to $75 from $155 at Wells Fargo
- Genedx Earnings Call Resets Outlook Amid Strong Growth